Chronic Kidney Disease

Patients with HIV who are diagnosed with chronic kidney disease have a higher burden of serious clinical events.

Jaclyn Harth, PharmD, clinical assistant professor, Fairleigh Dickinson School of Pharmacy, discusses the role of the health system pharmacist for patients with chronic hyperkalemia. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

A recent study showed that effective lifestyle behavioral changes for patients with chronic kidney disease frequently involved education, goal setting, feedback, monitoring, and social support.

A retrospective cohort study was the second largest evaluation to date of sodium polystyrene sulphonate use and safety in patients with chronic kidney disease.

A study using genomics and proteomics identified new subtypes of clear cell renal cell carcinoma based on tumor microenvironment signatures.

More men than women initiate kidney replacement therapy despite a higher prevalence of chronic kidney disease seen in women.

A study published in the Clinical Journal of American Society of Nephrology found that a healthy dietary pattern may prevent chronic kidney disease (CKD) and albuminuria.

A recent study suggests that hyperkalemia and uncomplicated hyperglycemia in patients treated in the emergency department is commonly caused by iatrogenesis.

Neither vitamin D nor omega-3 fatty acid supplementation were found to significantly inhibit changes in serum creatinine and cystatin C decline over 5 years among adults with type 2 diabetes.

Roxadustat for the treatment of patients with anemia from chronic kidney disease was shown to have positive efficacy and no increased cardiovascular risk in patients dependent and not dependent on dialysis.

The oral therapy is indicated to act as both a monotherapy and a combination therapy to improve glycemic control. It is also indicated to prevent cardiovascular and renal death in patients with CKD.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than 661,000 Americans have kidney failure.

According to the CDC, approximately 1 of 3 patients with type 1 and 2 diabetes mellitus (DM) has CKD. What do we need to know about patients with DM and CKD?

High consumption of sugary beverages has previously been linked to obesity, diabetes, and some types of cancer.

A multimethod approach including use of refill data may be the most effective method to identify nonadherence in young patients with chronic kidney disease.

In an additional analysis from the CANVAS program, new data reinforce evidence of improved renal outcomes for those with type 2 diabetes and chronic kidney disease.

Screening for HBV among high-risk populations is crucial to stopping transmission of the virus.

HIV-positive patients need to maintain healthy body weight, quit smoking, eat well, exercise regularly and treat hypertension, diabetes and dyslipidemia.

Direct-acting antivirals drugs show similar cure rates in co-infected patients as high as mono-infected patients.

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.

Ferric citrate was originally approved for the control of serum phosphorus levels in patients with chronic kidney disease who require dialysis.

An aspirin a day may reduce their risk of hepatocellular carcinoma in patients with hepatitis B virus.

Patients with chronic kidney disease are at risk for several comorbid conditions, including cardiovascular disease.

Patients who develop chronic kidney disease (CKD) are at risk for a number of comorbidities, including cardiovascular decline.

Women with the hepatitis C virus have fewer live births and face a higher risk of miscarriage, infertility, gestational diabetes and pre-eclampsia.

Patients with stage 3 kidney disease cured of hepatitis C virus experienced an improvement in kidney function following treatment.

Sofosbuvir may help improve the kidney function of some patients with hepatitis C virus.

Results from the EMPA-REG OUTCOME trial suggests empagliflozin (Jardiance) has potential in the treatment of chronic kidney disease.

Epoetin alfa biosimilar has indications in cancer, HIV, and chronic kidney disease, among other conditions.